Drug vs Class-Specific Black Box Warnings: Does One Bad Drug Spoil the Bunch?

ArticleinJournal of General Internal Medicine 26(6):570-2 · April 2011with9 Reads
DOI: 10.1007/s11606-011-1714-9 · Source: PubMed
Since safety concerns regarding prescription drugs are often discovered only after a medicine has been approved and released on the market, FDA regulatory advisories serve as an important means of communicating risk information to providers and to the general public. Although there are a variety of methods that the FDA uses to communicate such information, black box warnings are reserved for those deemed of highest public health importance. In many cases, risk information may be available for only select drugs within a therapeutic class, and thus the Agency often has to decide how broadly an advisory shoul db e applied when faced with incomplete information. Should a warning derived from data about a single agent be similarly applied across drugs within the same chemical class or across agents with similar pharmacologic effects? Why or why not? What factors should guide this decision? As with many decisions that the Agency makes, this deliberation can be complex, since it requires the combination of facts and judgments in the setting of incomplete scientific information. To complicate matters further, advisories focused on a single agent may have substantially different effects than advisories focused on an entire therapeutic class. For example, applying an advisory to a single member of a class may erroneously suggest superior safety of other members of the class in the absence of evidence to the contrary, and may also erode a particular agent’s market share and thus be met with resistance by industry stakeholders. The lack of specificity of a class-wide warning may blunt the impact of an advisory. 1 Too many advisories may lead to “alert fatigue.” Poorly worded or framed advisories may increase their spillover to untargeted populations. Indeed, as the history of risk communication has shown us, poorly managed messages about risks can become risks themselves. 2,3
  • [Show abstract] [Hide abstract] ABSTRACT: Long-acting injectable (LAI) formulations of antipsychotics are valuable treatment alternatives for patients with psychotic disorders, and understanding their safe use is critical. Post-injection delirium/sedation syndrome (PDSS) has been reported following treatment with one atypical antipsychotic LAI. Clinical databases of risperidone LAI and paliperidone palmitate were explored to identify if cases of PDSS had been observed. No cases of PDSS were identified in 15 completed trials of 3,164 subjects (approximately 115,000 injections) or the postmarketing safety database of risperidone LAI. Only one case of PDSS was identified among 10 completed trials (3,817 subjects, 33,906 injections) of paliperidone palmitate—that case having been reported in a patient randomized to treatment with placebo. Examination of these prospective databases finds no evidence that risperidone LAI and paliperidone palmitate are associated with PDSS and suggest that findings seen with another antipsychotic LAI are not generalizable.
    Full-text · Article · Nov 2010
  • [Show abstract] [Hide abstract] ABSTRACT: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes. Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06). Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
    Full-text · Article · Jul 2007
  • [Show abstract] [Hide abstract] ABSTRACT: Cardiovascular disease remains the primary cause of mortality for patients with type 2 diabetes, which is characterized by insulin resistance. The thiazolidinediones (TZDs), also known as glitazones, are one of the pharmacological approaches to improve insulin sensitivity. At present, there are two available TZDs: pioglitazone and rosiglitazone. The common target of action for TZDs is the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma) that regulates the gene transcription involved in adipocyte differentiation and glucose and lipid metabolism. TZDs have shown similar effects on glycemic control, as well as on weight gain, fluid retention, increased risk of heart failure, and leg and forearm fractures. However, TZDs have differential effects on cardiovascular disease. This article will review the differential effects of pioglitazone and rosiglitazone on cardiovascular risk factors and outcomes, as well as the potential differences between them. Based upon available evidence, pioglitazone has a beneficial effect on cardiovascular disease. By contrast, it seems that rosiglitazone increases cardiovascular risk. The difference in lipid profile may be the main factor accounting for the superiority of pioglitazone in reducing cardiovascular risk.
    Article · Mar 2010
Show more